No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
656 |
4. Check minimum number of eventsNone |
656 |
5. Include endpointsNone |
656 |
6. Filter based on genotype QC (FinnGen only) |
656 |
Control definitions (FinnGen only)
- Control exclude
- H7_OPTNERVE
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Optic atrophy
based on the number of shared cases.
Similar with more cases:
- Other disorders of optic [2nd] nerve and visual pathways
- Disorders of optic nerve and visual pathways
- Diseases of the eye and adnexa
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 5582 | 2664 | 2879 |
| Only index persons | 4719 | 2320 | 2399 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.08 | 0.08 | 0.08 |
| Only index persons | 0.09 | 0.09 | 0.09 |
| Median age at first event (years) | |||
| Whole population | 46.61 | 48.27 | 44.98 |
| Only index persons | 45.82 | 47.26 | 44.44 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 656 | 349 | 307 |
| Unadjusted period prevalence (%) | 0.13 | 0.12 | 0.14 |
| Median age at first event (years) | 53.17 | 51.94 | 54.58 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 567
- Matched controls
- 5670
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H47.2
ICD-10 Finland
Optic atrophy
+∞
323.0
535
*
XCK00
NOMESCO Finland
Perimetry
19.9
135.4
217
171
H53.4
ICD-10 Finland
Visual field defects
30.4
76.3
103
41
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
9.3
70.3
160
230
H46
ICD-10 Finland
Optic neuritis
+∞
62.7
59
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
21.3
59.4
89
49
CS494
NOMESCO Finland
Other visual field testing
24.1
57.8
83
40
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.8
50.0
199
569
D32.02
ICD-10 Finland
Benign tumor of the meninges at the base of the brain
49.5
48.3
58
13
H47.0
ICD-10 Finland
Disorders of optic nerve, not elsewhere classified
+∞
45.4
43
*
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
6.7
45.2
126
233
H47.1
ICD-10 Finland
Papilloedema, unspecified
+∞
44.4
42
*
XCW99
NOMESCO Finland
Other investigative procedure of eye
5.7
43.7
140
308
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
7.9
43.1
105
159
CS424
NOMESCO Finland
Visual field testing with Goldmann perimetry
32.5
42.7
56
19
H54.2
ICD-10 Finland
Moderate visual impairment, binocular
37.1
42.5
54
16
G35
ICD-10 Finland
Multiple sclerosis
26.9
40.6
56
23
XCD10
NOMESCO Finland
Electrophysiological examination of eye
14.5
39.0
67
52
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
6.0
36.4
109
217
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
10.8
36.0
71
74
XCK10
NOMESCO Finland
Photography of fundus of eye
5.0
35.2
125
303
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
21.0
33.7
50
26
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
7.0
33.3
87
144
E23.00
ICD-10 Finland
Panhypopituitarism
96.0
33.1
36
*
AA1AD
NOMESCO Finland
CT of head and brain
3.4
31.7
195
766
109
Kela drug reimbursment
Multiple sclerosis
26.6
30.5
42
17
37790
ICD-8 Finland
Other diseases of retina and optic nerve, Atrophia (et degeneratio) nervi optici (tabica excepta)
+∞
29.4
28
*
TAB00
NOMESCO Finland
Lumbar puncture
7.8
29.3
70
101
101
Kela drug reimbursment
Anterior pituitary hypofunction
18.3
26.6
41
24
N86
ICPC
Multiple sclerosis
63.2
26.2
30
5
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
23.2
24.6
35
16
H02AB09
ATC
hydrocortisone; systemic
8.8
23.5
51
63
H47.3
ICD-10 Finland
Other disorders of optic disc
+∞
23.1
22
*
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
18.9
22.4
34
19
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
9.1
22.1
47
56
CS434
NOMESCO Finland
Visual field testing with Humphrey automated perimetry
11.9
21.3
39
35
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.3
21.2
83
216
AAF20
NOMESCO Finland
Revision of shunt of ventricle of brain
50.0
20.3
24
5
9530/0-C70.0
ICD-O-3
Meningioma, NOS, of cerebral meninges
21.7
20.1
29
14
G91.1
ICD-10 Finland
Obstructive hydrocephalus
59.8
20.0
23
*
N03AX14
ATC
levetiracetam; systemic
7.5
19.3
46
66
G40.9
ICD-10 Finland
Epilepsy, unspecified
6.8
19.1
49
78
3771A
ICD-9 Finland
Disorders of optic nerve and visual pathways, Optic atrophy
+∞
18.9
18
*
D32.00
ICD-10 Finland
Benign tumor of the meninges on the outer surface of the cerebrum
12.0
18.7
34
30
102
Kela drug reimbursment
Diabetes insipidus
68.9
17.8
20
*
CS5Z4
NOMESCO Finland
Specialised imaging for glaucoma
9.1
17.7
37
43
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
17.6
17.5
27
16
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
8.9
17.5
37
44
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
14.5
17.5
29
21
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
20.0
17.0
25
13
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
9.4
16.6
34
38
AAF05
NOMESCO Finland
Ventriculoperitoneal shunt
14.9
16.5
27
19
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
8.8
16.5
35
42
R5210
NOMESCO Finland
Assessment of the improvements needed in the living environment
41.4
16.4
20
5
R56.8
ICD-10 Finland
Other and unspecified convulsions
4.4
16.0
59
145
AAF25
NOMESCO Finland
Removal of shunt of ventricle of brain
164.3
15.6
16
*
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
9.1
15.4
32
37
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
18.4
15.3
23
13
G91.0
ICD-10 Finland
Communicating hydrocephalus
18.4
15.3
23
13
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.8
14.9
109
451
N03AG01
ATC
valproic acid; systemic, rectal
4.1
14.8
59
156
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
25.8
14.8
20
8
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
21.7
14.7
21
10
183
Kela drug reimbursment
Lamotrigin and topiramate
15.9
14.5
23
15
XA800
NOMESCO Finland
Neuropsychological investigation
4.4
14.2
52
127
AA7AA
NOMESCO Finland
Liquor cerebri shunt X-ray examinatin without contrast
35.0
13.6
17
5
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.8
13.4
95
385
N05BA09
ATC
clobazam; oral
13.4
13.0
22
17
3400A
ICD-9 Finland
Multiple sclerosis[SCLEROSIS MULTIPLEX (DISSEMINATA)]
71.5
12.6
14
*
N03AF02
ATC
oxcarbazepine; oral
5.3
12.5
38
76
H54.1
ICD-10 Finland
Severe visual impairment, binocular
132.8
12.5
13
*
L03AX13
ATC
glatiramer acetate; parenteral
38.4
12.3
15
*
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
38.4
12.3
15
*
CK2A4
NOMESCO Finland
Autofluorescence imaging of ocular fundus
27.4
12.1
16
6
L03AB07
ATC
interferon beta-1a; parenteral
21.8
12.1
17
8
SPAT1229
SPAT
Assessment of need for aid
3.3
12.0
63
209
H54.4
ICD-10 Finland
Blindness, monocular
30.7
11.7
15
5
A06AD11
ATC
lactulose; oral
2.4
11.5
103
473
SPAT1292
SPAT
Other function in accordance with SHToL (Finnish classification of nursing interventions)
3.1
11.5
66
233
N03AF01
ATC
carbamazepine; oral, rectal
3.9
11.5
47
128
D35.30
ICD-10 Finland
Craniopharyngoma
122.4
11.5
12
*
H49.0
ICD-10 Finland
Third [oculomotor] nerve palsy
25.6
11.2
15
6
D32.9
ICD-10 Finland
Benign neoplasm: Meninges, unspecified
18.2
10.8
16
9
H54.0
ICD-10 Finland
Blindness, binocular
112.0
10.5
11
*
34099
ICD-8 Finland
Multiple sclerosis
112.0
10.5
11
*
9530/0-C70.9
ICD-O-3
Meningioma, NOS, of meninges, NOS
112.0
10.5
11
*
T85.0
ICD-10 Finland
Mechanical complication of ventricular intracranial (communicating) shunt
+∞
10.4
10
*
H54.7
ICD-10 Finland
Unspecified visual loss
12.3
10.4
18
15
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
8.4
10.4
22
27
M03BX01
ATC
baclofen; systemic
8.1
10.2
22
28
WX882
NOMESCO Finland
High dependency care
4.2
9.8
36
89
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.2
9.7
111
569
ZXC95
NOMESCO Finland
Use of surgical navigator
8.6
9.6
20
24
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.7
9.6
68
276
N03AX16
ATC
pregabalin; oral
2.0
9.6
134
751
PA2LT
NOMESCO Finland
Endovascular closure of extensive brain aneurysm
101.7
9.4
10
*
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.2
9.4
103
519
H54.3
ICD-10 Finland
Mild or no visual impairment, binocular
30.6
9.4
12
*
H47.7
ICD-10 Finland
Disorder of visual pathways, unspecified
+∞
9.4
9
*
N05BA01
ATC
diazepam; systemic, rectal
2.4
9.4
87
405
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.9
9.4
184
1168
N04BB01
ATC
amantadine; oral
6.6
9.3
23
36
H53.1
ICD-10 Finland
Subjective visual disturbances
3.4
9.3
45
142
H53.2
ICD-10 Finland
Diplopia
4.9
9.2
29
62
AA1AA
NOMESCO Finland
Head X-ray examination
10.3
9.1
17
17
G80.1
ICD-10 Finland
Spastic diplegic cerebral palsy
37.3
9.0
11
*
CA1BG
NOMESCO Finland
Eye and orbita MRI examination with high intensity magnet
19.0
9.0
13
7
H01AC01
ATC
somatropin; parenteral
8.1
8.9
19
24
N03AX09
ATC
lamotrigine; oral
3.6
8.9
39
114
I67.1
ICD-10 Finland
Cerebral aneurysm, nonruptured
6.1
8.8
23
39
G40.12
ICD-10 Finland
Simple partial seizures with secondary generalization
10.9
8.8
16
15
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
3.4
8.8
42
131
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.2
8.8
45
148
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.2
8.8
99
506
H53.9
ICD-10 Finland
Visual disturbance, unspecified
4.8
8.7
28
61
-
ICD-10 Finland
NA
5.4
8.7
25
48
G93.2
ICD-10 Finland
Benign intracranial hypertension
50.8
8.7
10
*
PA2BC
NOMESCO Finland
Cerebral extensive angiography with X-ray
16.6
8.6
13
8
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
10.3
8.6
16
16
N03AB02
ATC
phenytoin; systemic
10.3
8.6
16
16
D44.3
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Pituitary gland
91.4
8.4
9
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
2.8
8.4
56
217
36703
ICD-8 Finland
Inflammation of optic nerve and retina, Neuritis optica, retrobulbaris
+∞
8.4
8
*
CS3P4
NOMESCO Finland
Optic nerve head stereophotography
11.0
8.3
15
14
H03AA01
ATC
levothyroxine sodium; systemic
1.9
8.2
129
755
AA1BM
NOMESCO Finland
MRI examination of brain with 3 Tesla magnet
8.3
8.1
17
21
H34.1
ICD-10 Finland
Central retinal artery occlusion
17.5
8.1
12
7
R3120
NOMESCO Finland
Training in mobility skills
33.9
8.1
10
*
CA1CM
NOMESCO Finland
Eye and orbita extensive MRI examination with 3 Tesla magnet
33.9
8.1
10
*
R2120
NOMESCO Finland
Counselling and guidance concerning rehabilitation services and social security
10.2
8.1
15
15
R51.80
ICD-10 Finland
Headache
2.1
8.0
89
452
G81.9
ICD-10 Finland
Hemiplegia, unspecified
8.6
7.9
16
19
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
11.0
7.8
14
13
114
Kela drug reimbursment
Glaucoma
2.6
7.8
56
227
R4160
NOMESCO Finland
Other therapy enhancing rehabilitation
4.7
7.8
25
55
OAB43
SPAT
NA
0.3
7.8
13
465
D32.0
ICD-10 Finland
Benign neoplasm: Cerebral meninges
15.3
7.7
12
8
L04AA27
ATC
fingolimod; oral
45.6
7.7
9
*
2132
FHL
Ventricular operators sunt
45.6
7.7
9
*
164
Kela drug reimbursment
Fingolimod
45.6
7.7
9
*
G40.21
ICD-10 Finland
Partial epileptic seizure with cloudiness and automatism
18.7
7.6
11
6
H52.1
ICD-10 Finland
Myopia
4.2
7.6
27
66
SPAT1216
SPAT
Assessment of functional ability
2.1
7.6
93
493
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.7
7.6
234
1685
ZXA10
NOMESCO Finland
Bilateral
1.9
7.5
114
654
Z96.1
ICD-10 Finland
Presence of intraocular lens
2.2
7.5
80
399
WYA30
NOMESCO Finland
Preparations for expected poor cooperation
2.5
7.5
60
259
G80.9
ICD-10 Finland
Cerebral palsy, unspecified
81.1
7.4
8
*
E23.2
ICD-10 Finland
Diabetes insipidus
81.1
7.4
8
*
H35.5
ICD-10 Finland
Hereditary retinal dystrophy
13.6
7.4
12
9
N03AX12
ATC
gabapentin; oral
2.1
7.4
85
437
N03AE01
ATC
clonazepam; systemic
3.1
7.3
39
133
AAC00
NOMESCO Finland
Ligature of intracranial aneurysm
9.5
7.3
14
15
N03AX18
ATC
lacosamide; systemic
9.5
7.3
14
15
E22.80
ICD-10 Finland
Central precocious puberty
+∞
7.3
7
*
Q85.09
ICD-10 Finland
Unspecified neurofibromatosis
+∞
7.3
7
*
E89.30
ICD-10 Finland
Postprocedural hypopituitarism
+∞
7.3
7
*
9380/3-C71.9
ICD-O-3
Glioma, malignant of brain, NOS
+∞
7.3
7
*
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
+∞
7.3
7
*
E23.09
ICD-10 Finland
Pituitary insufficiency NOS
+∞
7.3
7
*
N03AX11
ATC
topiramate; oral
4.4
7.3
25
59
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.8
7.3
157
1016
Q85.00
ICD-10 Finland
Neurofibromatosis, type 1
30.4
7.2
9
*
R1230
NOMESCO Finland
Neuropsychological evaluation of need and possibilities to rehabilitation
5.7
7.1
19
34
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.2
7.1
71
345
PAW37
NOMESCO Finland
Biopsy of temporal artery
11.1
6.8
12
11
G40.19
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
9.5
6.8
13
14
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.6
6.8
223
1615
G93.0
ICD-10 Finland
Cerebral cysts
40.5
6.8
8
*
RS222
NOMESCO Finland
NA
7.3
6.7
15
21
NK6MA
NOMESCO Finland
Measurement of bone age from hand and elbow using X-ray
4.5
6.7
22
50
N05CD08
ATC
midazolam; nasal, systemic
4.1
6.7
24
60
N31.1
ICD-10 Finland
Reflex neuropathic bladder, not elsewhere classified
12.4
6.6
11
9
EBA15
NOMESCO Finland
Extraction of large number of teeth
3.2
6.6
32
103
N31.2
ICD-10 Finland
Flaccid neuropathic bladder, not elsewhere classified
10.2
6.6
12
12
H26.4
ICD-10 Finland
After-cataract
2.4
6.5
54
238
R1220
NOMESCO Finland
Psychological examination of need and possibilities to rehabilitation
6.3
6.5
16
26
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
2.8
6.5
39
145
L04AX07
ATC
dimethyl fumarate; oral
70.6
6.4
7
*
G40.1
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
70.6
6.4
7
*
H54.5
ICD-10 Finland
Severe visual impairment, monocular
14.5
6.4
10
7
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
3.0
6.3
36
127
ZXC86
NOMESCO Finland
Use of endoscopic device
11.2
6.3
11
10
A02BC03
ATC
lansoprazole; oral
1.7
6.3
154
1028
A28
ICPC
Limited function/disability NOS
2.0
6.3
87
482
G81.1
ICD-10 Finland
Spastic hemiplegia
18.3
6.3
9
5
RS140
NOMESCO Finland
NA
18.3
6.3
9
5
37799
ICD-8 Finland
Other diseases of retina and optic nerve, Unspecified
+∞
6.3
6
*
9350/1-C75.2
ICD-O-3
Craniopharyngioma, NOS, of craniopharyngeal duct
+∞
6.3
6
*
G91.8
ICD-10 Finland
Other hydrocephalus
+∞
6.3
6
*
G40.20
ICD-10 Finland
Complex partial seizures with only alteration of consciousness
7.8
6.1
13
17
H90.3
ICD-10 Finland
Sensorineural hearing loss, bilateral
1.9
6.1
91
516
N06AB04
ATC
citalopram; systemic
1.8
6.1
111
674
H25.8
ICD-10 Finland
Other senile cataract
2.2
6.1
60
290
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
12.7
6.1
10
8
XKC03
NOMESCO Finland
Water cystometry
3.6
6.1
25
71
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
4.2
6.1
21
51
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
2.7
6.1
39
150
XCH05
NOMESCO Finland
Eye pressure longterm registration
10.2
6.1
11
11
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
5.3
6.1
17
33
ZXA00
NOMESCO Finland
Right side
1.7
6.1
146
967
XKD00
NOMESCO Finland
Uroflowmetry
2.0
6.0
83
457
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
63
119
5.75
32.46
1.5
1.7
636.7
421.3
mg/l
0.77
58
110
56
108
5.58
28.16
1.4
1.7
3.8
3.7
mmol/l
0.24
51
100
54
106
5.46
26.62
1.9
1.7
25.5
13.1
e6/l
0.27
43
85
54
106
5.46
26.62
1.9
1.8
1350.1
1184.3
e6/l
0.05
43
87
26
26
10.37
23.07
2.2
1.3
—
—
—
0
0
25
25
10.36
22.17
1.1
1.0
1.5
1.1
u/l
—
9
14
32
45
7.42
21.80
2.0
1.3
—
—
—
0
0
27
37
7.57
18.78
1.0
1.0
—
—
—
0
0
131
614
2.42
16.53
11.6
7.2
—
—
—
0
0
117
530
2.47
15.86
3.9
2.0
376.0
361.1
nmol/l
0.09
108
488
29
55
5.47
14.78
1.1
1.1
—
—
—
0
0
27
48
5.82
14.72
1.0
1.1
—
—
—
0
0
24
38
6.52
14.64
1.1
1.1
239.6
197.2
mg/l
0.68
19
32
33
71
4.84
14.62
1.2
1.1
—
—
—
0
0
22
32
7.08
14.50
5.3
2.8
—
—
—
0
0
28
54
5.37
14.02
1.1
1.1
—
—
—
0
0
13
0
+∞
13.59
1.3
0.0
—
—
—
0
0
22
36
6.29
13.00
5.4
2.7
11.9
12.6
%
0.09
17
24
33
80
4.29
12.64
4.6
5.2
461.2
373.8
umol/l
1.90
26
72
15
16
9.57
12.59
1.1
1.0
1818.1
1369.0
miu/ml
0.54
15
16
21
34
6.35
12.53
2.1
1.7
—
—
—
0
0
239
1551
1.85
12.17
2.6
2.1
191.3
251.3
u/l
0.56
220
1468
332
2397
1.78
11.73
11.1
7.2
1.2
1.2
mmol/l
1.08
306
2193
145
809
2.02
11.54
2.3
2.3
28.9
29.7
s
1.26
138
787
48
162
3.12
11.35
2.8
1.5
6.5
9.2
u/l
0.68
35
131
354
2623
1.76
11.26
10.6
7.6
1.2
1.2
mmol/l
0.04
311
2254
400
3081
1.76
11.00
7.7
5.5
6.7
6.7
mmol/l
0.03
387
2879
16
24
6.81
10.22
2.6
3.3
28.7
34.7
umol/l
—
10
17
143
837
1.91
9.76
2.0
1.9
—
—
—
0
0
300
2195
1.68
9.41
6.7
5.3
35.2
35.7
g/l
0.87
279
2048
22
49
4.61
9.36
5.8
2.2
1069.1
719.6
e6/l
—
8
18
69
311
2.36
9.32
1.7
1.7
—
—
—
0
0
351
2690
1.66
9.08
8.0
6.6
10.6
12.6
umol/l
2.62
326
2539
424
3413
1.69
9.05
7.3
4.3
37.4
2627.0
e6/l
—
7
50
128
756
1.86
8.41
7.1
6.2
1.0
1.1
mmol/l
0.80
121
702
476
3993
1.70
8.28
9.6
7.4
83.3
81.7
u/l
0.22
443
3747
186
1232
1.71
8.26
3.0
2.3
—
—
—
0
0
275
2023
1.62
8.09
2.1
1.9
95.0
94.8
pmol/l
0.03
159
1064
142
882
1.78
7.87
5.0
3.9
0.8
0.8
mmol/l
0.19
136
830
384
3112
1.56
7.13
13.4
9.2
4.5
4.0
e9/l
2.30
349
2708
257
1913
1.56
6.91
4.9
3.3
—
—
—
0
0
468
4008
1.59
6.50
5.0
3.9
14.9
14.7
pmol/l
0.82
422
3650
80
440
1.93
6.48
2.4
2.4
4.0
7.3
ug/l
2.80
64
388
99
584
1.82
6.45
1.9
1.9
—
—
—
0
0
100
594
1.81
6.37
10.6
9.9
13.8
12.4
kpa
1.32
94
568
100
594
1.81
6.37
10.6
10.0
5.1
5.1
kpa
0.29
95
566
15
34
4.49
6.26
1.2
1.1
—
—
—
0
0
139
913
1.66
6.18
3.1
2.9
1.0
0.9
e6/l
0.24
82
517
99
593
1.79
6.13
1.9
1.9
—
—
—
0
0
138
915
1.64
5.90
1.8
1.7
1236.0
1209.5
nmol/l
0.12
107
705
98
594
1.76
5.82
10.8
10.0
0.9
1.1
mmol/l
0.17
73
468
74
411
1.90
5.82
6.8
5.2
2.0
1.6
mmol/l
0.43
63
301
33
132
2.58
5.79
4.3
3.3
39.7
35.9
umol/l
0.32
28
112
37
158
2.42
5.67
1.7
1.5
0.1
0.1
iu/ml
—
5
33
94
568
1.76
5.64
9.3
5.1
2.1
1.7
mmol/l
0.54
79
452
166
1163
1.57
5.63
8.2
3.9
1.0
1.0
kg/l
0.04
19
174
271
2127
1.47
5.30
3.0
2.4
78.9
76.0
nmol/l
0.76
242
1926
58
307
1.98
5.26
1.6
1.4
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
14
35
4.07
5.19
1.1
1.1
—
—
—
0
0
43
207
2.15
5.02
2.3
2.0
—
—
—
0
0
162
1156
1.53
5.00
1.6
1.5
19.4
20.2
nmol/l
0.26
141
990
56
301
1.94
4.87
2.4
3.5
4.4
4.6
pmol/l
0.77
50
269
33
144
2.36
4.85
1.5
1.4
—
—
—
0
0
584
5403
1.74
4.72
26.1
16.3
139.6
139.7
mmol/l
0.16
569
5254
27
109
2.54
4.68
1.5
1.4
—
—
—
0
0
27
109
2.54
4.68
1.5
1.4
—
—
—
0
0
584
5420
1.71
4.44
25.7
16.4
4.0
4.0
mmol/l
1.28
567
5261
11
27
4.13
4.17
1.2
1.0
—
—
—
0
0
9
13
7.00
4.17
1.9
2.0
25.8
15.7
umol/l
—
9
13
528
4816
1.49
4.01
5.2
4.6
1.9
2.1
mu/l
0.43
474
4415
81
517
1.65
3.98
2.6
2.6
0.2
0.2
g/l
0.36
76
488
69
422
1.71
3.98
4.4
2.2
12.4
13.0
nmol/l
0.30
62
367
307
2556
1.38
3.96
6.3
3.6
0.0
0.0
estimate
0.00
39
466
191
1470
1.42
3.91
3.7
3.2
0.5
0.4
e6/l
0.25
146
1100
25
108
2.37
3.80
1.6
1.5
—
—
—
0
0
171
1303
1.42
3.68
2.6
2.2
3.3
3.0
mg/l
0.98
143
1121
31
593
0.50
3.62
1.5
2.1
—
—
—
0
0
10
26
3.89
3.53
2.6
1.8
201.2
118.2
ng/l
—
10
20
176
1357
1.41
3.53
7.7
4.0
0.0
0.0
estimate
0.69
38
460
65
405
1.67
3.52
2.4
2.7
71.9
67.2
ml/min/173m2
0.38
28
172
37
196
1.94
3.41
2.1
1.8
—
—
—
0
0
306
2591
1.34
3.36
6.3
3.6
0.0
0.0
estimate
0.80
41
454
568
5312
1.52
3.29
21.9
14.0
28.1
23.0
mg/l
2.03
467
4155
302
2565
1.33
3.20
7.7
4.9
0.0
0.0
estimate
0.50
40
470
28
530
0.51
3.18
1.5
2.0
—
—
—
0
0
237
1945
1.34
3.17
4.2
3.6
75.0
38.6
ng/l
0.52
187
1329
32
166
1.98
3.15
3.1
3.1
152.8
184.9
%
2.01
32
161
37
204
1.86
3.05
1.6
2.1
1.6
1.5
g/l
0.24
32
180
60
381
1.63
3.04
2.0
1.6
—
—
—
0
0
17
69
2.50
2.98
1.3
1.3
—
—
—
0
0
8
18
4.49
2.80
4.9
2.1
—
—
—
0
0
31
170
1.86
2.63
1.6
1.6
—
—
—
0
0
11
38
2.93
2.59
2.5
2.7
—
—
—
0
0
8
209
0.38
2.58
1.4
1.5
—
—
—
0
0
280
2404
1.29
2.58
4.3
4.0
—
—
—
0
0
30
164
1.87
2.57
3.6
3.1
—
—
—
0
0
87
628
1.44
2.49
4.4
4.3
31.1
31.4
%
0.11
64
421
8
21
3.84
2.47
2.4
2.5
112.9
101.1
ug/l
—
8
21
33
190
1.78
2.42
4.0
3.1
96.5
88.4
%
1.70
33
179
10
34
2.97
2.42
1.8
1.4
—
—
—
0
0
5
8
6.29
2.37
2.2
3.1
—
—
—
0
0
29
162
1.83
2.35
1.4
1.4
330.8
304.8
ug/g
0.22
14
96
96
714
1.40
2.34
2.7
2.5
21.1
22.4
%
0.35
84
610
26
455
0.55
2.33
1.4
1.7
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
30
171
1.79
2.28
3.4
3.2
0.4
0.3
u/ml
0.33
18
100
22
113
1.98
2.28
9.3
9.3
1208.2
212.2
iu/ml
—
9
24
8
23
3.51
2.27
1.1
1.1
—
—
—
0
0
209
1755
1.28
2.23
3.5
3.4
2.4
2.4
mmol/l
0.10
172
1545
113
871
1.36
2.22
3.2
3.0
2.5
1.9
e6/l
0.31
55
480
179
1479
1.29
2.16
3.5
3.2
1227.1
1354.1
ng/l
0.23
154
1251
106
813
1.36
2.15
2.7
2.5
12.2
13.1
umol/l
0.58
93
749
193
1611
1.28
2.15
2.6
2.6
50.5
56.7
u/l
2.40
174
1492
205
1727
1.27
2.12
5.1
3.5
42.7
32.7
u/l
0.78
191
1652
99
756
1.36
2.07
2.6
2.5
2.2
2.4
g/l
1.26
86
700
424
3898
1.25
1.98
4.6
4.1
12.9
11.6
mm/h
0.96
396
3604
68
492
1.43
1.95
4.0
2.4
32.8
139.2
u/l
0.55
58
414
6
17
3.55
1.84
1.2
1.2
—
—
—
0
0
12
53
2.29
1.81
3.1
2.4
—
—
—
0
0
9
35
2.59
1.80
1.1
1.3
—
—
—
0
0
9
35
2.59
1.80
1.3
1.1
—
—
—
0
0
585
5620
1.38
1.79
15.0
10.2
27.6
26.7
u/l
0.30
564
5426
9
36
2.52
1.74
1.1
1.3
—
—
—
0
0
139
1143
1.27
1.73
2.0
1.9
1.3
1.2
mg/l
0.10
100
871
228
1986
1.23
1.70
7.0
3.8
—
—
—
0
0
115
931
1.29
1.62
3.7
3.0
2.5
2.4
mmol/l
1.12
96
812
12
56
2.16
1.62
1.6
1.7
—
—
—
0
0
34
223
1.55
1.60
3.1
1.5
16.8
24.2
iu/l
0.74
29
187
7
26
2.71
1.58
1.0
1.0
—
—
—
0
0
79
610
1.34
1.57
6.2
3.1
6.4
8.1
umol/l
0.86
71
534
12
57
2.13
1.56
2.7
3.0
2.7
6.6
nmol/l
0.75
12
57
18
100
1.82
1.54
2.1
1.8
—
—
—
0
0
16
86
1.88
1.51
1.3
1.2
2.8
4.4
u/ml
—
6
36
23
140
1.67
1.47
2.3
1.8
—
—
—
0
0
5
16
3.14
1.44
1.0
1.1
—
—
—
0
0
5
16
3.14
1.44
1.0
1.1
—
—
—
0
0
38
263
1.47
1.42
7.4
4.3
25.2
24.9
mmol/l
0.17
38
256
15
81
1.87
1.41
1.3
1.2
5.8
4.5
u/ml
—
6
24
14
74
1.91
1.40
1.1
1.7
—
—
—
0
0
18
104
1.75
1.38
2.2
2.1
133.7
131.9
g/l
—
9
76
5
17
2.96
1.36
1.2
1.2
—
—
—
0
0
23
144
1.62
1.33
1.9
1.8
—
—
—
0
0
25
160
1.58
1.33
1.8
1.2
—
—
—
0
0
21
129
1.65
1.31
1.3
1.7
—
—
—
0
0
23
145
1.61
1.30
1.7
1.6
—
—
—
0
0
6
24
2.51
1.30
4.2
2.9
373.2
710.7
u/ml
—
6
24
16
91
1.78
1.30
2.3
2.3
16.9
16.5
%
—
7
43
11
55
2.02
1.28
2.1
1.2
—
—
—
0
0
14
77
1.84
1.26
1.4
1.6
—
—
—
0
0
6
25
2.41
1.24
1.0
1.6
—
—
—
0
0
8
36
2.24
1.24
1.7
1.3
—
—
—
0
0
17
101
1.70
1.21
1.1
1.0
—
18.9
—
0
5
6
26
2.32
1.19
3.0
2.2
—
—
—
0
0
6
26
2.32
1.19
3.0
2.2
—
—
—
0
0
23
149
1.56
1.18
1.3
1.2
—
24.9
—
0
6
0
33
0.00
1.16
0.0
7.4
—
37.0
—
0
11
8
39
2.06
1.15
1.0
1.2
—
—
—
0
0
0
36
0.00
1.14
0.0
1.3
—
—
—
0
0
7
31
2.27
1.10
2.1
4.1
99.9
89.6
%
—
7
31
14
81
1.74
1.09
1.1
1.1
—
—
—
0
0
5
21
2.39
1.09
1.0
1.3
—
—
—
0
0
5
21
2.39
1.09
1.0
1.2
14.1
8.9
ug/l
—
5
21
5
21
2.39
1.09
1.0
1.6
—
—
—
0
0
11
59
1.88
1.08
2.7
4.0
—
—
—
0
0
45
341
1.34
1.06
7.7
4.7
130.8
127.5
g/l
0.51
45
336
24
162
1.50
1.05
2.5
2.2
12417.4
4375.5
u/l
—
6
62
183
1628
1.17
1.04
4.4
4.7
1.8
2.4
ug/l
1.23
160
1467
11
190
0.57
1.04
3.2
1.9
—
—
—
0
0
77
630
1.25
1.04
37.4
22.9
1.2
1.3
inr
—
8
86
5
22
2.28
1.03
1.0
1.6
—
—
—
0
0
5
22
2.28
1.03
3.6
2.5
—
—
—
0
0
18
114
1.60
1.03
2.7
1.6
—
—
—
0
0
11
60
1.85
1.03
1.6
1.6
91.1
90.3
%
0.14
11
60
11
60
1.85
1.03
1.5
1.3
0.5
0.6
nmol/l
0.84
11
55
86
1027
0.81
1.02
1.5
1.6
—
—
—
0
0
20
132
1.53
0.98
2.4
1.8
2.7
5.8
iu/l
—
5
40
14
85
1.66
0.95
1.1
1.6
—
—
—
0
0
6
27
2.23
0.93
3.2
2.2
—
—
—
0
0
500
4811
1.17
0.92
17.8
12.7
84.0
82.2
ml/min/173m2
0.94
420
3948
12
71
1.70
0.89
2.4
2.0
—
—
—
0
0
8
42
1.92
0.89
1.0
1.2
—
70.4
—
0
7
246
2265
1.14
0.86
3.2
2.8
140.2
122.1
ug/l
0.57
220
2100
432
4510
0.88
0.86
24.5
17.1
13.8
13.6
%
2.17
424
4435
17
112
1.53
0.85
1.0
1.2
—
2.2
—
0
9
368
3482
1.13
0.82
5.1
3.2
60.0
48.4
u/l
1.29
342
3271
13
81
1.62
0.81
2.8
1.9
—
—
—
0
0
23
164
1.42
0.81
1.4
1.2
—
—
—
0
0
13
82
1.60
0.78
1.5
1.6
—
—
—
0
0
23
166
1.40
0.76
1.4
1.2
—
—
—
0
0
6
34
1.77
0.76
1.3
1.4
—
—
—
0
0
169
1531
1.14
0.75
3.8
4.0
9.8
10.2
mg/mmol
0.06
104
979
5
24
2.09
0.74
1.0
1.2
166.8
111.7
iu/ml
—
5
24
15
100
1.51
0.73
1.5
1.6
—
—
—
0
0
518
5026
1.15
0.72
4.9
4.4
5.8
6.0
mmol/l
1.70
467
4609
5
26
1.93
0.70
1.6
1.3
—
—
—
0
0
5
26
1.93
0.70
1.6
1.3
—
—
—
0
0
5
29
1.73
0.64
1.0
2.1
—
—
—
0
0
5
29
1.73
0.64
1.0
2.1
—
—
—
0
0
8
49
1.64
0.62
1.0
1.2
—
84.3
—
0
7
5
30
1.67
0.61
6.2
2.8
—
73860.5
—
0
6
23
299
0.76
0.60
2.5
1.9
—
—
—
0
0
603
5935
1.20
0.60
32.2
20.6
133.5
135.7
g/l
3.21
592
5847
8
54
1.49
0.57
2.6
1.8
—
—
—
0
0
8
54
1.49
0.57
1.5
1.4
—
—
—
0
0
6
36
1.67
0.57
3.0
1.9
—
—
—
0
0
6
36
1.67
0.57
3.0
1.9
—
—
—
0
0
6
36
1.67
0.57
3.0
1.9
—
—
—
0
0
6
36
1.67
0.57
3.0
1.9
—
—
—
0
0
174
1608
1.11
0.56
3.2
3.4
7.3
7.8
mmol/l
0.68
149
1359
21
159
1.33
0.56
1.0
1.1
—
—
—
0
0
6
98
0.61
0.52
1.3
1.3
—
—
—
0
0
9
65
1.39
0.50
2.4
1.8
—
—
—
0
0
9
65
1.39
0.50
2.4
1.8
—
—
—
0
0
9
65
1.39
0.50
2.4
1.8
—
—
—
0
0
5
83
0.60
0.46
1.4
1.6
—
—
—
0
0
7
51
1.38
0.44
1.1
1.0
—
—
—
0
0
338
3507
0.93
0.44
3.1
3.1
—
—
—
0
0
5
31
1.62
0.43
1.6
1.4
—
—
—
0
0
5
31
1.62
0.43
1.6
1.4
—
—
—
0
0
5
33
1.52
0.41
9.8
3.0
—
—
—
0
0
5
33
1.52
0.41
1.2
1.4
0.7
1.0
g/l
—
5
33
0
15
0.00
0.41
0.0
1.0
—
4.1
—
0
10
15
114
1.32
0.41
1.1
1.2
—
—
—
0
0
81
733
1.12
0.40
1.5
1.4
—
—
—
0
0
16
124
1.30
0.39
4.7
2.2
0.0
0.0
g/l
0.00
16
115
17
133
1.29
0.39
4.5
2.1
0.1
0.0
g/l
0.15
17
123
498
5078
0.92
0.39
4.7
4.3
1.4
1.5
mmol/l
1.88
453
4700
41
355
1.17
0.38
1.3
1.2
124.3
166.5
iu/ml
0.26
17
145
16
125
1.29
0.37
4.7
2.2
0.0
0.0
g/l
0.00
16
115
142
1332
1.08
0.35
3.3
2.8
332.2
6205.1
umol/l
4.60
119
1165
106
985
1.09
0.33
3.5
3.9
685.2
409.3
ng/l
0.23
76
765
7
52
1.35
0.31
1.4
1.2
—
—
—
0
0
89
958
0.92
0.29
2.9
2.9
0.7
0.7
ug/l
0.07
61
612
137
1296
1.07
0.28
3.9
4.1
21.7
20.8
%
0.22
57
577
19
158
1.21
0.28
1.4
1.3
—
—
—
0
0
8
64
1.25
0.27
1.0
1.1
—
—
—
0
0
20
236
0.84
0.27
2.3
1.9
—
—
—
0
0
136
1290
1.07
0.26
1.3
1.3
0.9
1.5
u/ml
0.85
25
326
5
71
0.70
0.26
1.4
1.5
—
—
—
0
0
14
114
1.23
0.25
2.1
1.5
—
—
—
0
0
17
143
1.19
0.23
1.5
1.3
—
—
—
0
0
111
1051
1.07
0.23
1.8
1.7
471.5
5688723.5
pmol/l
0.50
91
879
27
306
0.88
0.23
1.0
1.0
—
—
—
0
0
80
853
0.93
0.22
1.2
1.3
5.0
11.9
u/ml
1.31
25
340
5
40
1.25
0.22
1.0
1.1
—
—
—
0
0
5
40
1.25
0.22
1.0
1.1
—
—
—
0
0
5
41
1.22
0.22
1.0
1.1
—
—
—
0
0
5
41
1.22
0.22
1.0
1.1
—
—
—
0
0
5
41
1.22
0.22
1.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
1.7
—
0
6
0
11
0.00
0.21
0.0
1.0
—
32.3
—
0
6
0
11
0.00
0.21
0.0
1.0
—
27.4
—
0
11
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
8
103
0.77
0.21
1.4
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
20
176
1.14
0.17
4.0
2.1
—
—
—
0
0
37
401
0.92
0.16
3.0
3.2
356.5
213.0
ng/l
0.50
37
364
135
1398
0.96
0.16
1.7
1.7
1.5
1.4
mmol/l
0.36
116
1192
63
666
0.94
0.15
2.0
1.8
1.5
1.5
%
0.21
53
597
31
284
1.10
0.15
1.5
1.3
—
—
—
0
0
10
118
0.85
0.14
1.7
1.4
—
—
—
0
0
10
84
1.19
0.14
6.9
3.1
52.4
56.8
%
—
10
84
31
286
1.09
0.13
4.9
2.9
0.1
0.2
e6/l
1.42
31
278
20
181
1.11
0.12
1.2
2.1
—
—
—
0
0
15
133
1.13
0.12
1.6
1.3
—
—
—
0
0
90
870
1.04
0.10
1.2
1.3
54.5
34.9
iu/ml
0.29
15
278
5
48
1.04
0.09
1.0
1.4
—
—
—
0
0
6
58
1.03
0.08
2.7
2.2
19.2
17.6
ug/l
—
6
58
479
4760
1.02
0.08
6.1
5.6
39.5
39.8
mmol/mol
0.32
439
4448
7
82
0.85
0.07
1.4
1.1
—
—
—
0
0
487
4897
0.98
0.07
23.0
15.4
39.1
40.0
%
1.27
312
3669
13
118
1.10
0.07
1.1
1.2
—
—
—
0
0
49
507
0.96
0.06
4.1
4.5
191.1
34.0
ug/l
0.40
39
421
513
5111
1.02
0.04
4.6
4.3
4.6
4.6
mmol/l
1.22
469
4758
50
514
0.97
0.04
4.1
3.2
—
—
—
0
0
492
4901
1.02
0.04
4.2
3.9
1.4
1.3
mmol/l
2.37
446
4513
519
5199
0.99
0.01
5.0
4.8
2.7
2.8
mmol/l
0.40
474
4812
14
135
1.04
0.00
2.1
2.5
145.2
73.0
ug/min
—
9
77
15
151
0.99
0.00
1.3
1.3
—
—
—
0
0
7
71
0.99
0.00
2.0
1.5
—
—
—
0
0
5
50
1.00
0.00
1.0
1.6
—
—
—
0
0
7
71
0.99
0.00
2.0
1.5
—
—
—
0
0
7
69
1.01
0.00
2.0
1.5
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
7
69
1.01
0.00
2.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
9
96
0.94
0.00
1.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
5
49
1.02
0.00
1.0
1.1
—
—
—
0
0
7
69
1.01
0.00
2.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
8.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
9
91
0.99
0.00
3.4
4.5
120.7
350.4
u/ml
—
9
85
14
140
1.00
0.00
1.2
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
7
70
1.00
0.00
2.0
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
9.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
52.4
—
0
5
Mortality – FinRegistry
↥Association
Association between endpoint H7_OPTATROPHY and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_OPTATROPHY | 1.873 [1.59, 2.2] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.028 |
During the follow-up period (1.1.1998 — 31.12.2019), 468 out of 2068 females with H7_OPTATROPHY died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_OPTATROPHY | 2.259 [1.92, 2.65] | < 0.001 |
| Birth year | 0.987 [0.98, 1.0] | 0.005 |
During the follow-up period (1.1.1998 — 31.12.2019), 615 out of 2171 males with H7_OPTATROPHY died.
Mortality risk
Mortality risk for people of age
years, who have H7_OPTATROPHY.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.093% | 0.426% |
| 5 | 0.802% | 2.635% |
| 10 | 2.178% | 6.444% |
| 15 | 4.039% | 11.908% |
| 20 | 7.47% | 19.895% |
Relationships between endpoints
↥Index endpoint: H7_OPTATROPHY – Optic atrophy
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data